ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a U.S.-based biopharmaceutical company developing antibody therapies and therapeutic vaccines for neurodegenerative and other protein-misfolding diseases. Its research platform uses protein biology, physics, and supercomputing to identify disease-specific epitopes and design selective therapeutics and diagnostics, with a focus on Alzheimer’s disease, multiple system atrophy, and ALS.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueSelective antibodies designed to target toxic misfolded proteins in neurodegenerative disease.
Vaccine candidates intended to generate immune responses against disease-specific protein conformations.
Computational and protein-biology tools used to identify disease-specific epitopes and candidates.
Research efforts aimed at detecting toxic misfolded proteins for disease identification.
Potential future value from collaborations, licenses, or strategic transactions.
Customers
ProMIS does not sell commercial products today; its near-term counterparties are research partners, clinical investigators, regulators, and potential licensing or collaboration partners. If its programs advance, the eventual customers would be healthcare providers and patients in specialty neurology markets, but the business model is still centered on development-stage value creation rather than product sales.
Potential partners that may license assets, fund development, or co-develop programs.
Hospitals and research centers that enroll patients and generate clinical data for PMN310 and other programs.
Agencies that review safety, biomarker, and efficacy data before any approval path.
Patients with Alzheimer’s disease, MSA, ALS, and other protein-misfolding disorders.
Strategy
ProMIS is focused on advancing its lead Alzheimer’s program PMN310 while continuing to build a pipeline across other protein-misfolding diseases. Its strategy depends on progressing preclinical and clinical work, refining biomarker and trial design, and securing external funding or partnerships to support development.
The lead Alzheimer’s asset is central to the company’s value creation and partnering potential.
A broader portfolio can reduce single-asset dependence and expand partnering options.
Development-stage biotech requires ongoing capital to fund trials and regulatory work.
Geography
ProMIS is headquartered in the United States and its disclosures are presented in U.S. dollars. Its development work is organized around clinical and research activities rather than a manufacturing footprint, so geography mainly reflects where trials, collaborators, and capital markets are located.
Risks
The company faces the typical risks of development-stage biotechnology, including clinical failure, regulatory setbacks, and the need for substantial external funding. Its disclosures also highlight going-concern uncertainty and a material weakness in internal control over financial reporting, both of which can affect execution and investor confidence.
- Funding shortfallImpact: CriticalLikelihood: High
The company has no revenue and needs additional capital to continue development and operations.
Exposure - Going-concern uncertaintyImpact: CriticalLikelihood: High
Management disclosed substantial doubt about the ability to continue as a going concern.
Exposure: Near-term liquidity and operations
- Clinical development failureImpact: HighLikelihood: High
Drug candidates may not show sufficient safety or efficacy in preclinical or clinical studies.
Exposure: PMN310 and other pipeline assets
- Internal control weaknessImpact: HighLikelihood: High
A material weakness can delay reliable reporting and undermine investor confidence.
Exposure: Financial reporting and controls
- Regulatory and commercialization riskImpact: HighLikelihood: High
Even successful candidates require approvals, manufacturing readiness, and market access.
Exposure: Future product launch
Accounting
Judgemental itemsManagement must estimate unpaid clinical, CRO, and consultant costs, which can shift period expenses.
Impact: Affects operating expenses and liabilities
Equity awards to employees and directors can be a significant non-cash expense in development-stage biotech.
Impact: Affects operating loss and equity
Cash runway judgments influence disclosure and investor assessment of solvency risk.
Impact: Affects financial statement presentation and risk perception
ATM sales, PIPEs, warrants, and pre-funded warrants require careful classification and issuance-cost treatment.
Impact: Affects equity balances and financing cash flow presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
BioVie Inc
BIVIW · Pharmaceutical Preparations
NeuroSense Therapeutics Ltd.
NRSNW · Pharmaceutical Preparations
Praxis Precision Medicines, Inc.
PRAX · Pharmaceutical Preparations
Jupiter Neurosciences, Inc
JUNS · Pharmaceutical Preparations
Assembly Biosciences, Inc
ASMB · Pharmaceutical Preparations
Last updated: 24/09/2026